Literature DB >> 10528174

Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis.

A Lobell1, R Weissert, S Eltayeb, C Svanholm, T Olsson, H Wigzell.   

Abstract

We here study the adjuvant properties of immunostimulatory DNA sequences (ISS) and coinjected cytokine-coding cDNA in suppressive vaccination with DNA encoding an autoantigenic peptide, myelin basic protein peptide 68-85, against Lewis rat experimental autoimmune encephalomyelitis (EAE). EAE is an autoaggressive, T1-mediated disease of the CNS. ISS are unmethylated CpG motifs found in bacterial DNA, which can induce production of type 1 cytokines in vertebrates through the innate immune system. Because ISS in the plasmid backbone are necessary for efficient DNA vaccination, we studied the effect of one such ISS, the 5'-AACGTT-3' motif, in our system. Treatment with a DNA vaccine encoding myelin basic protein peptide 68-85 and containing three ISS of 5'-AACGTT-3' sequence suppressed clinical signs of EAE, while a corresponding DNA vaccine without such ISS had no effect. We further observed reduced proliferative T cell responses in rats treated with the ISS-containing DNA vaccine, compared with controls. We also studied the possible impact of coinjection of plasmid DNA encoding rat cytokines IL-4, IL-10, GM-CSF, and TNF-alpha with the ISS-containing DNA vaccine. Coinjection of IL-4-, IL-10-, or TNF-alpha-coding cDNA inhibited the suppressive effect of the DNA vaccine on EAE, whereas GM-CSF-coding cDNA had no effect. Coinjection of cytokine-coding cDNA with the ISS-deficient DNA vaccine failed to alter clinical signs of EAE. We conclude that the presence of ISS and induction of a local T1 cytokine milieu is decisive for specific protective DNA vaccination in EAE.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10528174

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Protective DNA vaccination against organ-specific autoimmunity is highly specific and discriminates between single amino acid substitutions in the peptide autoantigen.

Authors:  R Weissert; A Lobell; K L de Graaf; S Y Eltayeb; R Andersson; T Olsson; H Wigzell
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

2.  A single intrathecal injection of DNA and an asymmetric cationic lipid as lipoplexes ameliorates experimental autoimmune encephalomyelitis.

Authors:  Srikanth Yellayi; Brendan Hilliard; Mustafa Ghazanfar; Akivaga Tsingalia; Michael H Nantz; Laura Bollinger; Fabian de Kok-Mercado; James G Hecker
Journal:  Mol Pharm       Date:  2011-07-19       Impact factor: 4.939

Review 3.  Gene therapy in experimental autoimmune encephalomyelitis.

Authors:  P M Mathisen; V K Tuohy
Journal:  J Clin Immunol       Date:  2000-09       Impact factor: 8.317

Review 4.  Vaccines for multiple sclerosis: progress to date.

Authors:  Jorge Correale; Mauricio Farez; Wendy Gilmore
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

5.  Targeting innate receptors with MIS416 reshapes Th responses and suppresses CNS disease in a mouse model of multiple sclerosis.

Authors:  Madeleine White; Gill Webster; David O'Sullivan; Sarrabeth Stone; Anne Camille La Flamme
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

6.  Impaired autoimmune T helper 17 cell responses following DNA vaccination against rat experimental autoimmune encephalomyelitis.

Authors:  Asa Andersson; Magnus Isaksson; Judit Wefer; Anna Norling; Amilcar Flores-Morales; Fredrik Rorsman; Olle Kämpe; Robert A Harris; Anna Lobell
Journal:  PLoS One       Date:  2008-11-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.